<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04028232</url>
  </required_header>
  <id_info>
    <org_study_id>18512</org_study_id>
    <nct_id>NCT04028232</nct_id>
  </id_info>
  <brief_title>Influence of Socio-Economic Factor on Net Survival in Patients With Multiple Sclerosis in France ( ECOVIMUS).</brief_title>
  <acronym>ECOVIMUS</acronym>
  <official_title>Influence of Socio-Economic Factor on Net Survival in Patients With Multiple Sclerosis in France ( ECOVIMUS).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ecole des Hautes Etudes en Santé Publique</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Caen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: In comparison to general population, persons with Multiple Sclerosis have a
      higher risk to premature death with an estimate reduced life expectancy from 7 to 14 years.
      However, risk factors of mortality in MS are not well identified and well known. Following
      the example of studies carry on cancers survival, socioeconomic status (SES) may have an
      influence on survival in MS.

      Objective: The main objective of ECOVIMUS is to estimate net survival according to SES using
      the European Deprivation Index as a proxy and other major covariates (gender, initial
      clinical phase and years of disease onset).

      Methods: In order to answer to our main objective, we will use a retrospective cohort of MS
      patients with a medical follow-up in one of the 18 centers included in SURVIMUS II, with a MS
      onset between 1960 and 2015 and with an informed vital at the date of December 31st, 2015.

      The ecological score of deprivation EDI will be used as a proxy of the socioeconomic status
      and will be attributed from the geolocalisation to patient's residence address. Net survival
      is directly associated to the notion of &quot;mortality in excess&quot;. This mortality will be
      estimated comparing the observed mortality in MS patients to mortality in the general
      population. The advantage of this methodological approach is that cause of death is not
      needed.

      Statistical analysis: The influence of socioeconomic status on the excess of mortality will
      be estimated thanks to a parametric multivariate model of excess rate mortality. This model
      will be adjusted on other major covariates (gender, age at disease onset, and initial
      clinical phase) and will include potential complex effects as non-linearity,
      non-proportionality and interactions.

      Expected results: We expect to highlight some differences of net survival in MS patients
      according to socioeconomic group as it was already shown in cancers. This study will complete
      information on factors of mortality excess in MS and knowledge on socioeconomic inequalities
      encountered all along MS disease course.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 10, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Excess mortality survival</measure>
    <time_frame>From date of MS onset to the date of patients death or to study cut-off date on 1st January 2016.</time_frame>
    <description>Net survival is defined as the probability of death in a hypothetical setting where the cause of interest (in our case MS) would be the only possible cause of death. It is directly linked to the concept of the &quot;excess mortality due to the studied disease&quot;. Net survival can be calculated according to two settings, either the estimator of survival can be calculated from death due to MS while cause of death are known, either it can be calculated from the excess of mortality due to MS compared to the mortality of the general population obtained from mortality table of the generable population.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>European Deprivation Index (EDI) proxy of Socio-Economic Status</measure>
    <time_frame>From date of MS onset to the date of patients death or to study cut-off date on 1st January 2016.</time_frame>
    <description>The EDI Score is a combination of weighted ecological variates and is available for each 'IRIS area' (Ilots regroupés pour l'Information Statistique). An IRIS area represents the smallest geographical entity for which census data are available in France.
The geolocation of each individual address, according to latitude and longitude coordinates, is performed with the system of geographical information (SGI) ARGIS® 10.5. This point of geolocation is correlated to the IRIS area and then an EDI score can be attributed to patients registered in the database. The EDI score can be categorized into quintiles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distance to MS expert care center</measure>
    <time_frame>From date of MS onset to the date of patients death or to study cut-off date on 1st January 2016.</time_frame>
    <description>Distance in kilometer by road transport from residence place to MS expert care center</description>
  </secondary_outcome>
  <enrollment type="Anticipated">30000</enrollment>
  <condition>C10.114.375.500</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will include all patients registered in 17 selected French OFSEP
        centres with core dataset with a sufficient level of data (Besançon, Bordeaux, Caen,
        Clermont-Ferrand, Dijon, Lille, Lyon, Marseille, Nancy, Nice, Rennes, Saint-Etienne,
        Strasbourg, Toulouse, Montpellier, Nantes, Nîmes). The minimum required data includes:
        Diagnosis a of definite or probably MS according to Poser or McDonald criteria. With an MS
        onset date between January 1st, 1960 and December 31st, 2015. With a postal residence
        address well informed in the OFSEP database.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all patients registered in 17 selected French OFSEP centres with core dataset with a
             sufficient level of data

          -  Diagnosis a of definite or probably MS according to Poser or McDonald criteria. With
             an MS onset date between January 1st, 1960 and December 31st, 2015.

          -  With a postal residence address well informed in the OFSEP database.

        Exclusion Criteria:

          -  MS patients with less than one year's disease duration by the study end will be
             excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>100 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Gilles-Louis DEFER, Professor</last_name>
    <phone>0033231064617</phone>
    <email>defer-gi@chu-caen.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Floriane CALOCER, PharmD/PhD Student</last_name>
    <phone>0033231064617</phone>
    <email>calocer-fl@chu-caen.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Center of CAEN</name>
      <address>
        <city>Caen</city>
        <state>Normandy</state>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles-Louis DEFER, Professor</last_name>
      <phone>0033231064617</phone>
      <email>defer-gi@chu-caen.fr</email>
    </contact>
    <contact_backup>
      <last_name>Floriane CALOCER, PharmD/PhD</last_name>
      <phone>0033231064617</phone>
      <email>calocer-fl@chu-caen.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Eric BERGER, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claudine LEBRUN-FRENAY, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David BRASSAT, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David LAPLAUD, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jérôme DE SEZE, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruno BROCHET, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gilles DEFER, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gilles EDAN, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giovanni CASTELNOVO, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean PELLETIER, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Philippe CAMDESSANCHE, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre CLAVELOU, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre LABAUGE, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandra VUKUSIC, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thilbault MOREAU, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc DEBOUVERIE, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick VERMERSH, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Besancon</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric BERGER, Professor</last_name>
      <email>eberger@chu-besancon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno BROCHET, Professor</last_name>
      <email>bruno.brochet@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Centre of Caen</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles-Louis DEFER, Professor</last_name>
      <phone>0033231064617</phone>
      <email>defer-gi@chu-caen.fr</email>
    </contact>
    <contact_backup>
      <last_name>Floriane CALOCER, PharmD/PhD Student</last_name>
      <phone>0033231064617</phone>
      <email>calocer-fl@chu-caen.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital of Clermont Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre CLAVELOU, Professor</last_name>
      <email>pclavelou@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thibault MOREAU, Professor</last_name>
      <email>thibault.moreau@chu-dijon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick VERMERSCH, Professor</last_name>
      <email>patrick.vermersch@univ-lille2.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra VUKUSIC</last_name>
      <email>sandra.vukusic@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean PELLETIER, Professor</last_name>
      <email>jean.pelletier@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LABAUGE Pierre, Professor</last_name>
      <email>p-labauge@chu-montpellier.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Nancy</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc DEBOUVERIE, Professor</last_name>
      <email>m.debouverie@chu-nancy.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David LAPLAUD, Professor</last_name>
      <email>david.laplaud@univ-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Nice</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine LEBRUN-FRENAY, Professor</last_name>
      <email>lebrun-frenay.c@chu-nice.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University hospital Centre of Nîmes</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni CASTELNOVO, Professor</last_name>
      <email>giovanni.castelnovo@chu-nimes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles EDAN, Professor</last_name>
      <email>gilles.edan@chu-rennes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Centre of Saint-Etienne</name>
      <address>
        <city>Saint-Étienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-phillipe CAMDESSANCHE, Professor</last_name>
      <email>j.philippe.camdessanche@chu-st-etienne.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérôme DE SEZE, Professor</last_name>
      <email>jerome.de.seze@chru-strasbourg.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Centre of Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David BRASSAT, Professor</last_name>
      <email>brassat.d@chu-toulouse.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>July 19, 2019</study_first_submitted>
  <study_first_submitted_qc>July 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2019</study_first_posted>
  <last_update_submitted>January 22, 2020</last_update_submitted>
  <last_update_submitted_qc>January 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Epidemiology</keyword>
  <keyword>Socio-Economic Status</keyword>
  <keyword>Net Survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

